Published in J Outcome Meas on January 01, 1997
More relevant, precise, and efficient items for assessment of physical function and disability: moving beyond the classic instruments. Ann Rheum Dis (2006) 1.32
Using the PedsQL™ 3.0 asthma module to obtain scores comparable with those of the PROMIS pediatric asthma impact scale (PAIS). Qual Life Res (2011) 1.29
Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression. Psychol Assess (2014) 1.25
The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J Clin Epidemiol (2014) 1.16
Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS(®) Physical Function. J Gen Intern Med (2015) 0.94
Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis. Health Qual Life Outcomes (2013) 0.91
Linkage between the PROMIS(®) pediatric and adult emotional distress measures. Qual Life Res (2015) 0.88
Development of an Expanded Measure of Physical Functioning for Older Persons in Epidemiologic Research. Res Aging (2014) 0.84
Shouldn't we be making better use of the best available health measurement technologies? MedGenMed (2006) 0.75
Varying the item format improved the range of measurement in patient-reported outcome measures assessing physical function. Arthritis Res Ther (2017) 0.75
E pluribus unum: Harmonization of physical functioning across intervention studies of middle-aged and older adults. PLoS One (2017) 0.75
Comparison of rapid identification assays for Staphylococcus aureus. J Clin Microbiol (1984) 2.62
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Interlaboratory variation of antibiograms of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains with conventional and commercial testing systems. J Clin Microbiol (1983) 2.11
Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species. Antimicrob Agents Chemother (1984) 1.40
Shigellosis in day-care centres. Lancet (1975) 1.38
Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production. J Med Microbiol (1983) 1.29
Single-dose cefaclor therapy of urinary tract infection. Evaluation of antibody-coated bacteria test and C-reactive protein assay as predictors of cure. Am J Med (1981) 1.20
Study of teaching residents how to teach. J Med Educ (1988) 1.13
Evaluation of a teaching skills improvement programme for residents. Med Educ (1988) 1.09
Elevated mannose levels detected by gas-liquid chromatography in hydrolysates of serum from rats and humans with candidiasis. J Clin Microbiol (1982) 1.01
Role of imipenem/cilastatin in the treatment of soft tissue infections. Am J Med (1985) 1.01
Cefamandole and cefoxitin. Ann Intern Med (1985) 1.00
Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria. J Antimicrob Chemother (1986) 0.98
N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria. Antimicrob Agents Chemother (1982) 0.96
Long-term evaluation of training residents in clinical teaching skills. J Med Educ (1986) 0.94
Physical disability construct convergence across instruments: towards a universal metric. J Outcome Meas (1997) 0.92
Microbiologic and antibiotic aspects of infections in the oral and maxillofacial region. J Oral Surg (1979) 0.92
Synergism of oxacillin and gentamicin against enterococci. Antimicrob Agents Chemother (1975) 0.91
Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. J Antimicrob Chemother (1983) 0.89
In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides. Diagn Microbiol Infect Dis (1984) 0.89
Moxalactam in the therapy of serious infections. Antimicrob Agents Chemother (1982) 0.86
A research program for accountable and patient-centered health outcome measures. J Outcome Meas (1998) 0.84
Piperacillin v Carbenicillin in the therapy for serious infections. Arch Intern Med (1982) 0.83
Reliability of telemedicine examination. Telemed J (1997) 0.81
Case presentation format and clinical reasoning: a strategy for teaching medical students. Med Teach (1987) 0.78
Susceptibility patterns of bacteria following therapy with piperacillin. J Antimicrob Chemother (1982) 0.77
The design of isolation rooms. Infect Control Hosp Epidemiol (1996) 0.75
AIDS in Louisiana. Programs at Charity Hospital. J La State Med Soc (1987) 0.75
Evaluation of a teaching skills improvement program for residents. Res Med Educ (1987) 0.75
Determining the MICs of beta-lactams for Haemophilus. J Antimicrob Chemother (1987) 0.75
Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women. Am J Med (1985) 0.75
Apparent ketoconazole failure in candidal cholecystitis. Arch Intern Med (1982) 0.75
The association of fungi with sugarcane production and lung cancer mortality in Louisiana. J La State Med Soc (1983) 0.75